Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of$ 1.20. This compares to loss of $3.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this gene therapy company would post a loss of$ 1.27 per share when it actually produced a loss of $0.89, delivering a surprise of 29.92%.Over the last four quarters, the ...